In silico T cell epitope prediction identifies high value RH5 epitopes that correlate with response in vaccinees by Terry, F, Noe, A, Hindocha, P, Silk, S, Nielsen, C, Gupta, R, Kotraiah, V, Nugent, F, Minassian, A, Ardito, M, Soisson, L, Diggs, C, Miller, R, Moise, L, Martin, W, De Groot, A, Tucker, K, Phares, T, Ashfield, R, Gutierrez, G, Draper, S

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting by Healer, J, Thompson, JK, Mackwell, KL, Browne, CD, Seager, BA, Ngo, A, Lowes, KN, Silk, SE, Pulido, D, King, LDW, Christen, JM, Noe, AR, Kotraiah, V, Masendycz, PJ, Rajagopalan, R, Lucas, L, Stanford, MM, Soisson, L, Diggs, C, Miller, R, Youll, S, Wycherley, K, Draper, SJ, Cowman, AF

Efficacy of the novel Plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial by Minassian, A, Silk, S, Poulton, I, Mitton, C, Payne, R, Rawlinson, T, Barrett, J, Baker, M, Ramon, R, Lopez, F, Edwards, N, Ellis, K, Nielsen, C, Quinkert, D, Barfod, L, Miura, K, Diouf, A, Folegatti, P, Silman, D, Datoo, M, Smith, R, Berrie, E, Morelle, D, Lievens, M, Noe, A, Diggs, C, Soisson, L, Ashfield, R, Long, C, Nugent, F, Lawrie, A, Draper, S

Demonstration of the blood-stage controlled human malaria infection model to assess efficacy of the Plasmodium falciparum AMA1 vaccine FMP2.1/AS01 by Payne, R, Milne, K, Elias, S, Edwards, N, Douglas, A, Brown, R, Silk, S, Biswas, S, Miura, K, Roberts, R, Rampling, T, Venkatraman, N, Hodgson, S, Labbé, G, Halstead, F, Poulton, I, Nugent, F, de Graaf, H, Sukhtankar, P, Williams, N, Ockenhouse, C, Kathcart, A, Qabar, A, Waters, N, Soisson, L, Birkett, A, Cooke, G, Faust, S, Woods, C, Ivinson, K, McCarthy, J, Diggs, C, Vekemans, J, Long, C, Hill, A, Lawrie, A, Dutta, S, Draper, S